Paragon Care Limited · ASX:PGC
Paragon Care — 1H17 Earnings Presentation
14 slides from Paragon Care's earnings presentation, Feb 9, 2017
Slide 1: 1H17 Results Presentation
1H17 Results Presentation 9 February 2017 ASX ticker: PGC
Slide 2: Highlights
Highlights Record revenue and earnings growth with positive outlook for full year FY17 Revenue 1H17 Revenue of $55.0m, up 43% over 1H16 (1H16: $38.4m) Financial ‒ Underpinned by strong organic EBITDA growth of 14% on a like for like basis over $55.0m 43% performance the prior corresponding period wh
Slide 3: 1H17 Results: Financial highlights
1H17 Results 1H17 driven by strong organic growth with additional upside from acquisitions Financial highlights Record half year results across all key metrics — Revenue up 43% to $55.0m, driven by strong organic growth across all businesses including a full half year contribution from Western Biome
Slide 4: Strong underlying growth in operating cash flow
1H17 Results Strong underlying growth in operating cash flow Review of 1H17 operating cash flow Several one-off timing factors resulted in a reported net operating cash flow number which was lower than the underlying result 1H17 saw underlying net operating cash flow of $4.6m with the expectation th
Slide 5: Strong balance sheet supportive of future strategy
1H17 Results Strong balance sheet supportive of future strategy Balance sheet supportive of organic and inorganic growth During 1H17, the strength of Paragon’s balance sheet facilitated two acquisitions, funded investment in R&D to support organic growth and enabled strong growth in dividends Parago
Slide 6: FY17 Outlook
FY17 Outlook Paragon expects Paragon expectsa strong FY17 a strong fullfull FY17 yearyear result, with guidance showing double digit earnings growth result Second half of FY17 has started positively with continued FY17 full year result guidance subject to completion of the growth expected across all
Slide 7: Update on 1H17 Acquisitions
Update on 1H17 Acquisitions The recent acquisitions Acquisitions of MIDASofand MIDAS and Medical Electro Electro Medical were funded demonstrate via share continued issue and cash successful respectivelyofand execution represent significant upside potential to Paragon’s long term earnings strategy A
Slide 8: Product Update
Product Update Exciting new products in FY17 should continue to drive additional new revenue streams Rubbermaid Aged Care portfolio Recently added Rubbermaid Healthcare is a recognised Stralus Aged Care Beds are class-leading aged care beds leader in the development and manufacture of medical develo
Slide 9: Growth in FY17, FY18 & Beyond
Growth in FY17, FY18 & Beyond Paragon’s vision is to be Australia’s leading supplier of medical equipment, devices and consumables Growth Target revenue Strategy opportunities $250m Aspirational target driven by strong double digit To create a healthcare platform Highly fragmented industry, organic
Slide 10: Proven Execution
Proven Execution Paragon has a strong track record of buying sensibly and integrating successfully to support long- term growth Paragon’s management team has a proven track record acquiring and integrating 13 businesses over the last 7 years Acquisitions have supported growth in a highly fragmented
Slide 11: Share Price Catalysts
Share Price Catalysts Continued operational outperformance underpins potential for attractive risk-adjusted returns SYNERGIES Continue to leverage platform economics to drive organic revenue growth Platform economics by accessing new geographies, extending market reach and pursuing additional cross-
Slide 12: Company Highlights
Company Highlights A low-risk exposure to a rapidly growing health care company Paragon is one of the premier medical equipment, device and consumables suppliers on the ASX Platform economics, valuable distribution networks and a customer-centric business model Favourable macro tailwinds given the a
Slide 13: Corporate Overview
Corporate Overview Highly aligned Board and management team with a long term, supportive shareholder base Financial Information Board of Directors Share price (8-Feb-17) $0.815 Shane Tanner Mark Simari Number of shares (m) 164.6 Non-Executive Chairman Managing Director / Chief Executive Officer Mark
Slide 14: Thank You / Disclaimer
THANK YOU DISCLAIMER Some of the statements in this presentation constitute “forward-looking statements” that do not directly or exclusively relate to historical facts. These forward-looking statements reflect Paragon Care Limited’s current intentions, plans, expectations, assumptions and beliefs ab